Biological and Pharmaceutical Bulletin
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 17,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Sumio Ohtsuki
Faculty of Life Sciences, Kumamoto University
Read more
10,540 registered articles
(updated on June 18, 2021)
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
2019 Journal Impact Factor (JIF)
Scopus Pubmed
Featured article
Volume 44 (2021) Issue 6 Pages 747-761
Chrono-Drug Discovery and Development Based on Circadian Rhythm of Molecular, Cellular and Organ Level Read more
Editor’s picks

This review describes the chronotherapeutic strategies based on molecular clock system of chronopharmacokinetic, chronopharmacodynamic and cancer chronopathological factors in the xenobiotic detoxification, transporter, receptor and molecular target. Chronotherapeutic strategies focus on the monitoring of rhythm, overcoming rhythm disruption, manipulation of rhythm, chrono-therapeutic drug monitoring, chrono-drug delivery system and chrono-drug discovery. The screening for small molecules targeting the clock genes is now in progress to stabilize circadian phase and enhance circadian amplitude, thereby consolidating and coordinating circadian organization,. The academic research along with a combination of chemical and biological information is essential to promote the research and development of new modality drug discovery such as clock genes.

Volume 44 (2021) Issue 6 Pages 789-797
Acute Ramelteon Treatment Maintains the Cardiac Rhythms of Rats during Non-REM Sleep Read more
Editor’s picks

Ramelteon, a melatonin receptor agonist, has a sleep-promoting effect by modulating sleep-wake rhythms. To examine the effect of ramelteon on cardiac function, authors simultaneously recorded electrocardiograms, electromyograms, and electrocorticograms in the frontal cortex and the olfactory bulb of unrestrained rats treated with ramelteon. Authors demonstrated that during non-REM sleep, heartrate variability was maintained by ramelteon treatment. Analysis of the electromyograms confirmed that neither microarousal during non-REM sleep nor the occupancy of phasic periods during REM sleep was altered by ramelteon. Thus, authors propose a remedial effect of ramelteon on cardiac activity by keeping the heartrate variability.

Volume 44 (2021) Issue 6 Pages 804-815
Identification and Validation of Combination Plasma Biomarker of Afamin, Fibronectin and Sex Hormone-Binding Globulin to Predict Pre-eclampsia Read more
Editor’s picks

Numerous studies have confirmed that the sFlt1/PlGF ratio is a good predictor of the signs and symptoms of Pre-Eclampsia. However, its usefulness is limited to diagnosis after 20 weeks of gestation. To address this issue, in the present study the authors used plasma samples collected at gestational weeks 14-24 weeks from subjects who were subsequently diagnosed as Pre-Eclampsia. By employing SWATH-based proteomics for comprehensive discovery and SRM-based target quantification using in silico peptide selection criteria for validation, the authors were able to identify a 3-protein combination biomarker (AFAM, FINC and SHBG) that can predict effectively during gestational weeks 14-24 whether pregnant women would subsequently develop Pre-Eclampsia.

Volume 44 (2021) Issue 6 Pages 830-837
Protective Effect of Panduratin A on Cisplatin-Induced Apoptosis of Human Renal Proximal Tubular Cells and Acute Kidney Injury in Mice Read more
Editor’s picks

Cisplatin is an effective anti-cancer drug. A serious major side effect of cisplatin is an acute kidney injury. The authors demonstrated that panduratin A, a bioactive flavonoid, ameliorates cisplatin-induced nephrotoxicity by inhibition of cell apoptosis. The renoprotective effect of panduratin A is mediated by reducing oxidative stress and inhibiting ERK1/2 and caspase 3 activations. The protective effect of panduratin A did not impair the anti-cancer activity of cisplatin in cancer cells. Panduratin A might be a good candidate agent to alleviate cisplatin’s nephrotoxicity.

Volume 44 (2021) Issue 6 Pages 869-874
Assessment of Adherence to Post-exposure Prophylaxis with Oseltamivir in Healthcare Workers: A Retrospective Questionnaire-Based Study Read more
Editor’s picks

Influenza causes nosocomial outbreaks in healthcare settings. Post-exposure prophylaxis (PEP) for healthcare workers is one of the effective strategies for preventing outbreaks of influenza. However, PEP adherence in healthcare workers is rarely analysed. This retrospective questionnaire-based study showed that the adherence to PEP among healthcare workers was low, especially among physicians, and that the primary factor for preventing PEP adherence was misguided self-decision that continuation of PEP was unnecessary. This study emphasized that medication education should be provided to ensure treatment compliance and maximize the therapeutic benefits of PEP when PEP is administered.

View all featured articles
View all articles in Current issue
Most viewed articles May.2021
Share this page
Select past volume & issue
Announcements from publisher